Physician profile
Neil Levin
NPI 1487651675
$1,012.85
in general payments reported to CMS, 2019-2025
13 companies · $455 in 2025
The $455 reported for 2025 was more than what 82% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.05 · 2022: $30.35 · 2023: $149 · 2024: $337 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $940.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $189.14 | 2023-2025 | |
| Exact Sciences Corporation | $185.41 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $154.99 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $108.32 | 2024-2025 | Veozah |
| Novo Nordisk INC | $105.91 | 2019-2025 | Ozempic, Rybelsus |
| Sanofi Pasteur INC. | $56.61 | 2022-2025 | |
| Lilly USA, LLC | $52.97 | 2025 | Zepbound, Mounjaro |
| Dynavax Technologies Corporation | $51.36 | 2023-2024 | Heplisav-B |
| Amgen INC. | $36.53 | 2025 | Evenity |
| Madrigal Pharmaceuticals | $23.36 | 2025 | Rezdiffra |
| Abbvie INC. | $17.31 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $16.56 | 2025 | Eliquis |
| Horizon Therapeutics Plc | $14.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.